{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:09:01Z","timestamp":1795014541563,"version":"4.9.1"},"reference-count":41,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,10]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Pegylated IFN\u03b1 induces hematologic and molecular remission in CALR-mutated ET patients. The analysis of additional mutations highlights the presence of subclones with variable evolutions during IFN\u03b1 therapy.<\/jats:p>","DOI":"10.1182\/blood-2015-07-659060","type":"journal-article","created":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T22:54:12Z","timestamp":1445381652000},"page":"2585-2591","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":159,"title":["Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations"],"prefix":"10.1182","volume":"126","author":[{"given":"Emmanuelle","family":"Verger","sequence":"first","affiliation":[{"name":"Service de Biologie Cellulaire, Hopital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-3905","authenticated-orcid":false,"given":"Bruno","family":"Cassinat","sequence":"additional","affiliation":[{"name":"Service de Biologie Cellulaire, Hopital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Chauveau","sequence":"additional","affiliation":[{"name":"Laboratoire d\u2019Hematologie, Centre Hospitalier R\u00e9gional Universitaire de Brest, Brest, France;"},{"name":"Universit\u00e9 de Brest, Unit\u00e9 de Formation et de Recherche de medecine, Brest, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dosquet","sequence":"additional","affiliation":[{"name":"Service de Biologie Cellulaire, Hopital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Giraudier","sequence":"additional","affiliation":[{"name":"Laboratoire d\u2019Hematologie, Hopital Henri Mondor, Assistance Publique\u2013H\u00f4pitaux de Paris, Creteil, France;"},{"name":"Universit\u00e9 Paris 12, Creteil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Schlageter","sequence":"additional","affiliation":[{"name":"Service de Biologie Cellulaire, Hopital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Ianotto","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie Clinique, Institut de Canc\u00e9rologie, Centre Hospitalier R\u00e9gional Universitaire de Brest, Brest, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Al-Dewik","sequence":"additional","affiliation":[{"name":"Qatar Medical Genetic Center, Hamad Medical Corporation, Doha, Qatar;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Carillo","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Cytologie Clinique, Centre Hospitalier Universitaire de Nimes, Nimes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Legouffe","sequence":"additional","affiliation":[{"name":"Oncogard, Institut de Cancerologie du Gard, Nimes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Ugo","sequence":"additional","affiliation":[{"name":"Hematologie Biologique, Centre Hospitalier Universitaire Angers, Angers, France;"},{"name":"Universit\u00e9 d'Angers, Unit\u00e9 de Formation et de Recherche de Medecine, Angers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chomienne","sequence":"additional","affiliation":[{"name":"Service de Biologie Cellulaire, Hopital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"},{"name":"Universit\u00e9 Paris Diderot, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-438X","authenticated-orcid":false,"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Diderot, Paris, France; and"},{"name":"Centre d\u2019Investigations Cliniques, Hopital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7037","key":"2019111908083751200_B1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"23","key":"2019111908083751200_B2","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders.","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111908083751200_B3","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/sj.leu.2404214","article-title":"Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders.","volume":"20","author":"Kiladjian","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"2019111908083751200_B4","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"25","key":"2019111908083751200_B5","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms.","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111908083751200_B6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111908083751200_B7","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"2019111908083751200_B8","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111908083751200_B9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ajh.24037","article-title":"New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera.","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am J Hematol"},{"issue":"9","key":"2019111908083751200_B10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"2019111908083751200_B11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.7326\/0003-4819-119-11-199312010-00006","article-title":"Interferon-alpha 2b: a new treatment for polycythemia vera.","volume":"119","author":"Silver","year":"1993","journal-title":"Ann Intern Med"},{"issue":"6","key":"2019111908083751200_B12","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"issue":"32","key":"2019111908083751200_B13","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111908083751200_B14","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies.","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111908083751200_B15","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111908083751200_B16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms.","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111908083751200_B17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies.","volume":"12","author":"Shih","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"2019111908083751200_B18","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","article-title":"Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.","volume":"115","author":"Schaub","year":"2010","journal-title":"Blood"},{"issue":"22","key":"2019111908083751200_B19","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers.","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111908083751200_B20","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111908083751200_B21","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis.","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"2019111908083751200_B22","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111908083751200_B23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"p53 lesions in leukemic transformation.","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N Engl J Med"},{"issue":"50","key":"2019111908083751200_B24","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2019111908083751200_B25","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"2019111908083751200_B26","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells.","volume":"24","author":"Kiladjian","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2019111908083751200_B27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia.","volume":"371","author":"Cassinat","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111908083751200_B28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111908083751200_B29","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111908083751200_B30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4049\/jimmunol.1103405","article-title":"Hepatitis B virus-induced calreticulin protein is involved in IFN resistance.","volume":"189","author":"Yue","year":"2012","journal-title":"J Immunol"},{"key":"2019111908083751200_B31","article-title":"Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis [published online ahead of print August 25, 2015].","author":"Guglielmelli","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111908083751200_B32","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor imetelstat in patients with essential thrombocythemia.","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111908083751200_B33","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis.","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111908083751200_B34","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111908083751200_B35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a.","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111908083751200_B36","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111908083751200_B37","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"2019111908083751200_B38","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.","volume":"44","author":"Busque","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"2019111908083751200_B39","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies.","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"26","key":"2019111908083751200_B40","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes.","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111908083751200_B41","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/24\/2585\/1390027\/2585.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/24\/2585\/1390027\/2585.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T08:08:51Z","timestamp":1574150931000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/126\/24\/2585\/34707\/Clinical-and-molecular-response-to-interferon%CE%B1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,10]]},"references-count":41,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2015,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-07-659060","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,10]]}}}